Finanzen von Recursion Pharmaceuticals Inc (RXRX)RXRXRecursion Pharmaceuticals Inc

Evaluating the bottom line, Recursion Pharmaceuticals, Inc. maintains a gross margin of -49.82%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1759.69%, while the net margin is -1708.02%. These profitability ratios, combined with a Return on Equity (ROE) of -56.58%, provide a clear picture of how effectively RXRX converts its operational activities into shareholder value.

In the context of the broader market, RXRX competes directly with industry leaders such as NVAX and XERS. With a market capitalization of $2.18B, it holds a leading position in the sector. When comparing efficiency, RXRX's gross margin of -49.82% stands against NVAX's 78.27% and XERS's 83.47%. Such benchmarking helps identify whether Recursion Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Recursion's total revenue for Q2 2026 was $7.67 million, showing growth potential, but it reported a net income loss of $131 million, indicating ongoing financial challenges. The gross margin improved to -49.82% in Q2 2026, up from -183.81% in Q3 2025, suggesting a positive trend in profitability.